Redhill Biopharma earnings were -$8.3M for the trailing 12 months ending Dec 31, 2024, with -100% growth year over year. The latest RDHL earnings report on Dec 31, 2024 announced Q4 2024 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RDHL reported annual earnings of -$8.3M, with -134.6% growth. The next RDHL earnings date is Aug 14, 2025.
RDHL past earnings growth
How has RDHL's earnings growth performed historically?
What were Redhill Biopharma's earnings last quarter?
Redhill Biopharma (NASDAQ: RDHL) reported Q4 2024 earnings per share (EPS) of N/A, up N/A year over year. Total RDHL earnings for the quarter were N/A. In the same quarter last year, Redhill Biopharma's earnings per share (EPS) was N/A.
The next RDHL earnings date is Invalid Date. Add RDHL to your watchlist to be reminded of Redhill Biopharma's next earnings date.
Is Redhill Biopharma profitable or losing money?
As of the last Redhill Biopharma earnings report, Redhill Biopharma is currently losing money. Redhill Biopharma's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$8.27 million, a 134.57% decrease year over year.
What was RDHL's earnings growth in the past year?
As of Redhill Biopharma's earnings date in Q2 2025, Redhill Biopharma's earnings has grown -100% year over year. This is 101.62 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 1.62%. RDHL earnings in the past year totalled -$8.27 million.
What are Redhill Biopharma's earnings expectations?
The current EPS estimate for Redhill Biopharma's earnings report in Invalid Date is $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.